Affinage

DCTN1

Dynactin subunit 1 · UniProt Q14203

Length
1278 aa
Mass
141.7 kDa
Annotated
2026-04-28
52 papers in source corpus 13 papers cited in narrative 13 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DCTN1 encodes p150Glued, the largest subunit of the dynactin complex, which functions as a critical regulator of microtubule-based intracellular transport, cytoskeletal organization, and protein homeostasis. Its N-terminal CAP-Gly domain mediates direct microtubule binding, and disease-associated mutations in this domain impair microtubule affinity, disrupt dynactin localization, and promote TDP-43 cytoplasmic mislocalization and aggregation (PMID:33924373, PMID:24676999, PMID:41724579). DCTN1 directly binds TDP-43 through multiple domains and maintains TDP-43 nuclear localization; loss of DCTN1 function delays stress granule disassembly and drives formation of pathological ubiquitin-positive TDP-43 inclusions, linking dynactin-dependent transport to neurodegenerative proteinopathy (PMID:33924373, PMID:38311779). Beyond neuronal transport, DCTN1 regulates Cdc42/PAK2 signaling during osteoclastogenesis, contributes to sperm tail formation during spermiogenesis, and is required for normal neuromuscular junction integrity and motor function (PMID:32210358, PMID:21961240, PMID:37360176).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2010 Low

    Establishing that the DCTN1 ortholog functions as a motor adaptor directing kinesin-3-based cargo to specific neuronal compartments expanded its role beyond retrograde dynein transport to include anterograde motor complex targeting.

    Evidence Bimolecular fluorescence complementation in live C. elegans neurons showing DNC-1/UNC-104 complexes localized to axonal termini

    PMID:21195138

    Open questions at the time
    • Single BiFC method without functional rescue or mutagenesis
    • Not confirmed with mammalian DCTN1
    • Mechanism of compartment-specific targeting unclear
  2. 2011 Medium

    Demonstrating DCTN1 localization to sperm tails and its requirement for normal sperm tail morphogenesis revealed a non-neuronal developmental function for dynactin.

    Evidence Immunofluorescence localization and in vivo siRNA knockdown in mouse seminiferous tubules with sperm morphology analysis

    PMID:21961240

    Open questions at the time
    • Mechanism by which DCTN1 shapes sperm tail morphology unknown
    • No assessment of fertility outcome after knockdown
  3. 2014 Low

    Showing that Perry syndrome CAP-Gly mutations (F52L, and later K56R) reduce p150Glued microtubule binding provided the first mechanistic link between disease mutations and loss of dynactin–microtubule interaction.

    Evidence In vitro microtubule binding and co-sedimentation assays with mutant versus wild-type DCTN1 in cell lines

    PMID:24676999 PMID:27132499

    Open questions at the time
    • Single-method approaches without in vivo validation
    • Downstream consequences of impaired binding on cargo transport not measured
    • Structural basis of binding loss not resolved
  4. 2019 Medium

    Identifying the ubiquitin-proteasome system as the primary clearance pathway for both wild-type and G59S mutant DCTN1, with autophagy as backup, clarified protein quality control mechanisms relevant to mutant dynactin toxicity.

    Evidence Proteasome and autophagy inhibitor treatments combined with TFEB overexpression in cell culture, measuring aggregate burden and cell viability

    PMID:31654383

    Open questions at the time
    • In vivo validation of dual degradation pathway not performed
    • Whether other disease-linked mutants follow the same clearance hierarchy unknown
  5. 2020 Medium

    Discovery that DCTN1 acts upstream of Cdc42/PAK2 signaling to regulate osteoclast differentiation and survival established a non-transport signaling function for p150Glued in bone biology.

    Evidence siRNA knockdown with constitutively active Cdc42 rescue in osteoclastogenesis assays, plus in vivo bone erosion model

    PMID:32210358

    Open questions at the time
    • How DCTN1 activates Cdc42 mechanistically is unknown
    • Whether this function depends on intact dynein-dynactin transport or is independent
  6. 2021 Medium

    Mapping the multi-domain direct interaction between DCTN1 and TDP-43 revealed that DCTN1 actively maintains TDP-43 nuclear localization, and that the Perry mutation G71A disrupts this interaction, providing a molecular mechanism linking dynactin dysfunction to TDP-43 proteinopathy.

    Evidence Co-immunoprecipitation with truncation mutant panel and immunocytochemistry for TDP-43 localization in cultured cells

    PMID:33924373

    Open questions at the time
    • Whether DCTN1 transports TDP-43 via the dynein motor or acts independently is unclear
    • Endogenous-level interaction not validated
  7. 2023 Medium

    In vivo Drosophila loss-of-function studies established that DCTN1 is required for neuromuscular junction integrity and motor function, and that its loss alters splicing of synapse-related genes, suggesting broader gene-regulatory consequences.

    Evidence Tissue-specific RNAi in Drosophila neurons/muscles with behavioral assays, NMJ morphology analysis, and RNA-seq

    PMID:37360176

    Open questions at the time
    • Splicing alterations are correlative; direct versus indirect effects not distinguished
    • Whether mammalian DCTN1 loss produces analogous splicing changes untested
  8. 2024 Medium

    Connecting DCTN1 deficiency to impaired stress granule disassembly provided a mechanistic bridge between dynactin loss-of-function and TDP-43 inclusion pathology, showing that microtubule transport machinery is required for stress granule resolution.

    Evidence Live-imaging stress granule dynamics in DCTN1-knockdown cells plus Drosophila in vivo knockdown with ubiquitin/TDP-43 inclusion analysis

    PMID:38311779

    Open questions at the time
    • Whether stress granule disassembly defect is specific to DCTN1 or general to all dynactin subunits not resolved
    • Patient-derived cell validation lacking
  9. 2025 Medium

    Demonstrating that the DCTN1-RET oncogenic fusion activates RET kinase through DCTN1 coiled-coil domain-mediated dimerization showed how DCTN1 structural elements can be co-opted in cancer.

    Evidence CC-domain deletion mutagenesis with phosphorylation assays and in vivo tumor model with RET inhibitor rescue

    PMID:40155036

    Open questions at the time
    • Relevance limited to fusion-driven cancers; no evidence of native DCTN1 involvement in RET signaling
    • Frequency and clinical impact of DCTN1-RET fusions not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis for how DCTN1 coordinates TDP-43 nuclear-cytoplasmic transport with stress granule dynamics remains unresolved, and whether DCTN1's signaling roles (Cdc42/PAK2) depend on its canonical dynein-dynactin transport function is unknown.
  • No reconstituted in vitro system for DCTN1-mediated TDP-43 transport
  • No structural model of DCTN1–TDP-43 complex
  • Relationship between transport and signaling functions not dissected

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 4 GO:0060090 molecular adaptor activity 2
Localization
GO:0005856 cytoskeleton 4 GO:0005829 cytosol 2
Pathway
R-HSA-1852241 Organelle biogenesis and maintenance 3 R-HSA-162582 Signal Transduction 2 R-HSA-9612973 Autophagy 1
Partners
CDC42PAK2RETTDP-43UNC-104/KIF1A
Complex memberships
dynactin

Evidence

Reading pass · 13 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2021 DCTN1 directly binds TDP-43 through multiple domains: the CAP-Gly-basic supradomain, dynactin domain, and C-terminal region all interact with TDP-43, preferentially through TDP-43's C-terminal region. The Perry disease-linked G71A mutation reduces this TDP-43-interacting ability, and overexpression of DCTN1-G71A or the dynactin-domain or C-terminal fragments (but not the CAP-Gly-basic fragment) induces cytoplasmic mislocalization and aggregation of TDP-43. Co-immunoprecipitation, truncation mutant panel biochemical analysis, overexpression in cultured cells with immunocytochemistry International journal of molecular sciences Medium 33924373
2024 DCTN1 deficiency perturbs stress granule dynamics, specifically delaying stress granule disassembly in stressed cells, which drives the formation of pathological cytoplasmic TDP-43 inclusions. Genetic knockdown of DCTN1 in Drosophila accelerates formation of ubiquitin-positive TDP-43 cytoplasmic inclusions. Knockdown of other microtubule motor complex components (dynein, kinesin) also increased TDP-43 inclusions, indicating intracellular microtubule-based transport is required to prevent TDP-43 pathology. Drosophila genetic knockdown (in vivo), cultured cell stress granule assays (live imaging), immunofluorescence for ubiquitin/TDP-43 inclusions Acta neuropathologica communications Medium 38311779
2020 DCTN1 controls osteoclastogenesis by acting upstream of Cdc42/PAK2 signaling: RANKL-induced Cdc42 activation is blocked by DCTN1 knockdown, and constitutively active Cdc42 rescues osteoclast differentiation in DCTN1-silenced cells. DCTN1 also suppresses caspase-3 activation/apoptosis during osteoclastogenesis, and both knockdown and overexpression of DCTN1 are detrimental to osteoclast differentiation. siRNA knockdown, constitutively active Cdc42 rescue experiment, in vitro osteoclastogenesis assay, in vivo bone erosion animal model, western blot for NFATc1/c-Fos/PAK2 Experimental & molecular medicine Medium 32210358
2019 The ubiquitin-proteasome system is the primary degradation pathway for both wild-type and G59S mutant DCTN1 under normal conditions. When proteasome activity is inhibited, autophagy acts as a backup system to clear G59S DCTN1 aggregates. Overexpression of TFEB (a master autophagy regulator) promotes autophagic clearance of G59S DCTN1 aggregates and reduces G59S-induced cytotoxicity when proteasomes are impaired. Proteasome inhibitor treatment, autophagy inhibitor treatment, TFEB overexpression, cell viability assays, filter trap and western blot for aggregates Neurotoxicity research Medium 31654383
2014 The Perry syndrome-associated DCTN1 F52L mutation (and by implication other CAP-Gly domain mutations) impairs microtubule binding of p150Glued in vitro compared to wild-type dynactin p150Glued. In vitro microtubule binding assay with transfected mutant vs. wild-type DCTN1 in cell lines Movement disorders Low 24676999
2016 The DCTN1 p.K56R variant (adjacent to the CAP-Gly domain) reduces p150Glued affinity for microtubules and alters its cytoplasmic distribution to a more diffuse pattern in HEK293 cells compared to wild-type. Transfection of mutant vs. wild-type DCTN1 in HEK293 cells, microtubule co-sedimentation/binding assay, immunofluorescence Parkinsonism & related disorders Low 27132499
2020 Two DCTN1 mutations causing disease (c.626dupC frameshift and c.3823C>T missense) alter subcellular localization: the frameshift mutant is trapped in the nucleus and loses colocalization with α-tubulin, while the missense mutant forms cytoplasmic aggregates also losing α-tubulin colocalization, indicating loss of normal cytoskeletal association. In vitro transfection of mutant constructs, immunofluorescence co-localization with α-tubulin, western blot for truncated protein Annals of clinical and translational neurology Low 32023010
2011 Dctn1 (mouse ortholog) is localized primarily to the tail of spermatozoa, and siRNA-mediated knockdown in vivo via seminiferous tubule injection leads to significantly increased sperm tail abnormalities, establishing a role for DCTN1 in sperm tail formation during spermiogenesis. Western blot and immunofluorescence for localization, in vivo siRNA microinjection into seminiferous tubules, sperm morphology analysis Zhonghua nan ke xue Medium 21961240
2010 In C. elegans neurons, DNC-1 (the DCTN1 ortholog) acts as an adaptor for the kinesin-3 motor UNC-104(KIF1A); when UNC-104 is bound to DNC-1, the motor complex is specifically localized to axonal termini, in contrast to other adaptors that direct the motor to soma or along axons. Bimolecular fluorescence complementation (BiFC) assay in live C. elegans neurons to visualize motor-adaptor complexes and their subcellular distribution Neuroscience Low 21195138
2025 DCTN1-RET fusion activates RET kinase through DCTN1's coiled-coil (CC) domain-mediated dimerization; deletion of the CC domain abrogates dimer formation and reduces RET and ERK phosphorylation. Cells expressing DCTN1-RET show enhanced proliferation and tumorigenesis in vivo, suppressible by RET inhibitor TAS0286. Expression vector construction, stable cell lines with CC-domain deletion variants, in vitro phosphorylation assays, in vivo subcutaneous mouse tumor model, RET inhibitor treatment Anticancer research Medium 40155036
2023 Drosophila loss-of-function of Dctn1 (DCTN1 ortholog) in neurons or muscles causes motor defects (climbing, flight deficits). Global Dctn1 reduction reduces larval mobility and causes neuromuscular junction deficits. Transcriptome profiling reveals splicing alterations in genes required for synapse organization and function downstream of Dctn1 ablation. Tissue-specific RNAi knockdown in Drosophila, behavioral assays (climbing/flight), larval mobility assay, NMJ morphology analysis, RNA-seq Frontiers in neuroscience Medium 37360176
2024 Wild-type DCTN1 p150Glued suppresses aggregation of Perry disease-associated DCTN1 mutants when co-overexpressed, while motor neuron disease mutant aggregates are less affected by co-expressed wild-type protein, indicating distinct aggregation mechanisms for disease-associated mutant classes. Co-overexpression of wild-type and mutant DCTN1 constructs in HEK293T cells, immunofluorescence for aggregate formation Biological & pharmaceutical bulletin Low 38267040
2026 Perry disease-associated DCTN1 CAP-Gly domain variants (p.Arg32Cys, p.Gly67Ser, p.Gly71Arg) impair localization of p150Glued protein, induce TDP-43 pathology, and alter lysosomal positioning in functional cell studies. Next-generation sequencing for variant identification, functional studies in cell lines (localization by immunofluorescence, TDP-43 pathology assay, lysosomal positioning) Movement disorders Low 41724579

Source papers

Stage 0 corpus · 52 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 348 15326253
2005 Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Annals of neurology 155 16240349
2015 STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. Journal of hematology & oncology 80 26062823
2017 DCTN1-related neurodegeneration: Perry syndrome and beyond. Parkinsonism & related disorders 74 28625595
2014 DCTN1 mutation analysis in families with progressive supranuclear palsy-like phenotypes. JAMA neurology 47 24343258
2021 DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation. International journal of molecular sciences 33 33924373
2014 A novel DCTN1 mutation with late-onset parkinsonism and frontotemporal atrophy. Movement disorders : official journal of the Movement Disorder Society 33 24676999
2010 Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure. Movement disorders : official journal of the Movement Disorder Society 33 20437543
2016 DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism & related disorders 30 27132499
2010 Autonomic failures in Perry syndrome with DCTN1 mutation. Parkinsonism & related disorders 24 20702129
2017 DCTN1 gene analysis in Chinese patients with sporadic amyotrophic lateral sclerosis. PloS one 22 28792508
2021 DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 19 34014367
2018 DCTN1 F52L mutation case of Perry syndrome with progressive supranuclear palsy-like tauopathy. Parkinsonism & related disorders 17 29499916
2010 Sub-cellular distribution of UNC-104(KIF1A) upon binding to adaptors as UNC-16(JIP3), DNC-1(DCTN1/Glued) and SYD-2(Liprin-α) in C. elegans neurons. Neuroscience 16 21195138
2021 A novel Q93H missense mutation in DCTN1 caused distal hereditary motor neuropathy type 7B and Perry syndrome from a Chinese family. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 15 33443672
2019 Autophagy and Ubiquitin-Proteasome System Coordinate to Regulate the Protein Quality Control of Neurodegenerative Disease-Associated DCTN1. Neurotoxicity research 14 31654383
2014 In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Movement disorders : official journal of the Movement Disorder Society 14 24797316
2024 Dysregulation of stress granule dynamics by DCTN1 deficiency exacerbates TDP-43 pathology in Drosophila models of ALS/FTD. Acta neuropathologica communications 13 38311779
2020 The dynactin subunit DCTN1 controls osteoclastogenesis via the Cdc42/PAK2 pathway. Experimental & molecular medicine 13 32210358
2021 Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion. Thoracic cancer 12 34964276
1998 Human DCTN1: genomic structure and evaluation as a candidate for Alström syndrome. Genomics 12 9799602
2023 Reduced levels of ALS gene DCTN1 induce motor defects in Drosophila. Frontiers in neuroscience 10 37360176
2020 Larotrectinib followed by selitrectinib in a novel DCTN1-NTRK1 fusion undifferentiated pleomorphic sarcoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 10 32693686
2020 Novel destabilizing Dynactin variant (DCTN1 p.Tyr78His) in patient with Perry syndrome. Parkinsonism & related disorders 10 32712562
1998 The genomic structure of DCTN1, a candidate gene for limb-girdle muscular dystrophy (LGMD2B). Biochimica et biophysica acta 10 9805007
2020 New phenotype of DCTN1-related spectrum: early-onset dHMN plus congenital foot deformity. Annals of clinical and translational neurology 9 32023010
2017 Behavioral defects in a DCTN1G71A transgenic mouse model of Perry syndrome. Neuroscience letters 9 29273399
2021 An identical DCTN1 mutation in two Chinese siblings manifest as dHMN and ALS respectively: a case report. Amyotrophic lateral sclerosis & frontotemporal degeneration 8 34615428
2022 Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements. Thoracic cancer 7 35212154
2022 Spindle cell/sclerosing rhabdomyosarcoma with DCTN1::ALK fusion: broadening the molecular spectrum with potential therapeutic implications. Virchows Archiv : an international journal of pathology 7 35229187
2023 Perry syndrome: Novel DCTN1 mutation in a large kindred and first observation of prodromal disease. Parkinsonism & related disorders 6 37336025
2021 Behavioral profile in a Dctn1G71A knock-in mouse model of Perry disease. Neuroscience letters 6 34508845
2020 DCTN1-related Parkinson-plus disorder (Perry syndrome). Practical neurology 6 32434902
2007 The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis. Acta neurologica Scandinavica 6 17824900
2001 Genomic organization of the DCTN1-SLC4A5 locus encoding both NBC4 and p150(Glued). Cytogenetics and cell genetics 6 12063394
2024 Multisystem ALK-Positive Histiocytosis With DCTN1::ALK Fusion in an Adult, Responsive to Alectinib: Case Report and Literature Review. Journal of cutaneous pathology 5 39403984
2020 DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB. Neurobiology of aging 4 32402491
2011 [Location of Dctn1 in the mouse testis and sperm and its role in spermiogenesis]. Zhonghua nan ke xue = National journal of andrology 4 21961240
2020 A Novel Cosegregating DCTN1 Splice Site Variant in a Family with Bipolar Disorder May Hold the Key to Understanding the Etiology. Genes 3 32325768
2021 Novel Variants in the CLCN1, RYR2, and DCTN1 Found in Elderly Japanese Dementia Patients: A Case Series. Geriatrics (Basel, Switzerland) 2 33562224
2020 Perry syndrome: a case of atypical parkinsonism with confirmed DCTN1 mutation. The New Zealand medical journal 2 32325477
2025 Activation of DCTN1-RET Fusion Through Coiled-coil Domain as a Potential Target for RET Inhibitors. Anticancer research 1 40155036
2025 DCTN1-associated neurological disorder with symptoms similar to spinal bulbar muscular atrophy. Journal of neuromuscular diseases 1 40665686
2023 A Chinese pedigree with Perry disease caused by the p.Y78H mutation in DCTN1: A 6-year clinical follow-up. Behavioural brain research 1 36608707
2026 Pediatric intracranial inflammatory myofibroblastic tumor harboring DCTN1::ALK fusion: a case report with radiologic-pathologic-molecular correlation. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 0 41543587
2026 Novel Variants in DCTN1 Associated with Perry Disease: A Case Series from a Chinese Parkinsonism Cohort. Movement disorders : official journal of the Movement Disorder Society 0 41724579
2026 Case Report: imaging features of anaplastic lymphoma kinase-rearranged renal cell carcinoma with a novel DCTN1::ALK fusion. Frontiers in oncology 0 41883969
2025 Pediatric Cutaneous Anaplastic Lymphoma Kinase-Positive Histiocytosis with DCTN1::ALK Fusion: A Case Report and Literature Search. Diagnostics (Basel, Switzerland) 0 40361876
2025 Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboring DCTN1-ALK fusion: a case report and review. Frontiers in immunology 0 41246301
2025 Characterization of the genetic and clinical landscapes of DCTN1 gene in neurodegenerative diseases: a series of large case-control study. NPJ genomic medicine 0 41271780
2024 Wild-Type DCTN1 Suppresses the Aggregation of DCTN1 Mutants Associated with Perry Disease. Biological & pharmaceutical bulletin 0 38267040
2024 Clinical and neurophysiological characterization of p.Gly59Ser mutation in DCTN1: a study in a Thai family and a brief review. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 0 39395070